Clarity Pharmaceuticals to Present Prostate Cancer Data at EANM

Clarity Pharmaceuticals will present clinical data on its innovative copper-based SAR-bisPSMA diagnostic and therapeutic products at the upcoming European Association of Nuclear Medicine (EANM) Annual Congress 2026 in Vienna, Austria. The findings demonstrate superior tumor detection capabilities and deep, complete treatment responses in advanced prostate cancer patients.

The Australia-based clinical-stage radiopharmaceutical developer announced the official acceptance of its comprehensive medical data for the prestigious global conference. The upcoming presentations will highlight significant milestones achieved by both its diagnostic 64Cu-SAR-bisPSMA imaging agent and its targeted 67Cu-SAR-bisPSMA therapeutic pipeline.

A top-rated oral presentation will focus on the Co-PSMA investigator-initiated trial using 64Cu-SAR-bisPSMA. The trial evaluated patients suffering from biochemical recurrence of prostate cancer after undergoing a radical prostatectomy who exhibited low PSA levels.

The investigative product demonstrated superior diagnostic performance when evaluated head-to-head against the current standard-of-care 68Ga-PSMA-11 PET/CT scans. Key metrics showed an increased mean number of identified lesions at 1.26 compared to 0.48 for the standard scan.

The trial also revealed an elevated true positive rate of 71% versus 29% for the standard option. Furthermore, the overall proportion of trial participants returning a positive scan rose to 78% compared to just 36% under standard protocols.

Complementing the trial data, a three-patient case report showcased the unique ability of 64Cu-SAR-bisPSMA to successfully identify recurrent prostate cancer following negative results from standard-of-care scans. Next-day diagnostic imaging tracking the copper tracer revealed a 2.25-fold surge in detected lesions.

The next-day imaging sessions also recorded a 1.8-fold increase in tracer uptake. These clear visual insights immediately prompted changes in the planned clinical management for all three evaluated individuals.

The therapeutic efficacy of the company’s 67Cu-SAR-bisPSMA pipeline will be showcased via case reports from the ongoing Phase I/IIa SECuRE clinical trial. Two separate participants diagnosed with metastatic castration-resistant prostate cancer (mCRPC) reached entirely undetectable disease levels post-treatment.

The first patient recorded a sharp PSA level drop of 95.7% down to 0.26 ng/mL. The patient’s disease became completely undetectable following the third treatment cycle and remained undetectable at the 33-week mark, showing zero metastatic lesions on subsequent scans.

The second patient experienced a PSA level decline of 94.2% to 0.19 ng/mL. The individual achieved an undetectable disease status within 8 weeks of starting therapy, culminating in a confirmed complete clinical response.

Both trial participants experienced predominantly mild, short-lived adverse events. This safety profile strongly validates the commercial and clinical viability of using 67Cu-SAR-bisPSMA as a targeted therapeutic weapon against advanced prostate malignancies.

Dr. Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals, stated that these findings validate the company’s active, registrational Phase III clinical programs. The comparative data has continuously shown the asset outperforming standard imaging across multiple testing environments.

The formal acceptance of these abstracts at the 2026 EANM gathering highlights the clinical validity of Clarity’s manufacturing platform. It also underscores the potential for the SAR-bisPSMA suite to fundamentally upgrade the diagnostic and therapeutic paradigms within global oncology.

Financial tracking shows Clarity Pharmaceuticals Ltd. maintaining a current market capitalization of A$676.9 million. The company trades on public markets with an average daily volume of 2,570,818 shares, though short-term technical sentiment indicates a Sell signal.

Clinical Metric (Co-PSMA Trial)	64Cu-SAR-bisPSMA	Standard 68Ga-PSMA-11
Mean Lesions Detected	1.26	0.48
True Positive Rate	71%	29%
Positive Scan Proportion	78%	36%

Future Outlook

The positive data slated for the 2026 EANM Congress provides immediate momentum for Clarity’s ongoing Phase III registrational trials. By demonstrating clear diagnostic superiority over current standards like 68Ga-PSMA-11, the company is positioning its copper-paired portfolio to capture significant market share in the rapidly expanding radiopharmaceutical sector. If Phase III trials mirror these early diagnostic and therapeutic victories, the SAR-bisPSMA platform could redefine customized oncology care, offering a seamless “theranostic” system that images tumors one day and destroys them the next.

FAQs

What is Clarity Pharmaceuticals presenting at the 2026 EANM Congress?

Clarity Pharmaceuticals will present clinical data demonstrating the diagnostic superiority of its imaging agent, 64Cu-SAR-bisPSMA, and the strong therapeutic efficacy of its prostate cancer treatment, 67Cu-SAR-bisPSMA.

How did 64Cu-SAR-bisPSMA perform compared to the standard of care?

In the Co-PSMA trial, 64Cu-SAR-bisPSMA outperformed the standard 68Ga-PSMA-11 scan by discovering more lesions, achieving a higher true positive rate of 71% versus 29%, and expanding the total number of positive scans.

What therapeutic results did the SECuRE trial show for advanced prostate cancer?

The Phase I/IIa SECuRE trial revealed that two heavily pre-treated patients with metastatic castration-resistant prostate cancer achieved completely undetectable disease states and experienced PSA level reductions exceeding 94% after utilizing 67Cu-SAR-bisPSMA.